1-5 of 5
Oliver Gautschi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

Vivek Subbiah, Bhavana Konda, Todd Bauer, Caroline McCoach, Gerald Falchook, Masayuki Takeda, Jyoti Patel, Jared Weiss, Nir Peled, Lyudmila Bazhenova, Victoria Soldatenkova, Pearl French, Nora Drove, Oliver Gautschi, Alexander Drilon
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT011.
https://doi.org/10.1158/1538-7445.AM2021-CT011
Published: 01 July 2021
View article titled, Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers
Journal Articles

Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial

Rafael Rosell, Niki Karachaliou, Ana Giménez-Capitán, Carles Codony-Servat, Oliver Gautschi, Enriqueta Felip, Alessandra Curioni-Fontecedro, Solange Peters, Santiago Ponce-Aix, Martin Früh, Miklos Pless, Sanjay Popat, Sinead Cuffe, Paolo Bidoli, Adolfo Favaretto, Roswitha Kammler, Urania Dafni, Zoi Tsourti, Miguel Angel Molina-Vila, Rolf A. Stahel
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 269.
https://doi.org/10.1158/1538-7445.AM2016-269
Published: 15 July 2016
View article titled, Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial
Journal Articles

Abstract 2263: Autophagy protects against Src tyrosine kinase inhibitor treatment in non-small cell lung cancer cells via a novel miR-106a/ULK1 pathway

Sacha I. Rothschild, Oliver Gautschi, Jasmin Batliner, Melanie Jost, Martin F. Fey, Mathias Gugger, Mario P. Tschan
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2263.
https://doi.org/10.1158/1538-7445.AM2012-2263
Published: 15 April 2012
View article titled, Abstract 2263: Autophagy protects against Src tyrosine kinase inhibitor treatment in non-small cell lung cancer cells via a novel miR-106a/ULK1 pathway
Journal Articles

Abstract 3987: Src regulates inhibitor of differentiation 1 (Id1) via c-Myc induced repression of microRNA-29b: Implications for invasion of lung cancer cells and their resistance against Src inhibitors

Sacha I. Rothschild, Mario P. Tschan, Rolf Jaggi, Martin F. Fey, Mathias Gugger, Oliver Gautschi
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 3987.
https://doi.org/10.1158/1538-7445.AM2011-3987
Published: 15 April 2011
View article titled, Abstract 3987: Src regulates inhibitor of differentiation 1 (Id1) via c-Myc induced repression of microRNA-29b: Implications for invasion of lung cancer cells and their resistance against Src inhibitors
Journal Articles

Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer

Oliver Gautschi, Clifford G. Tepper, Phillip R. Purnell, Yoshihiro Izumiya, Christopher P. Evans, Tim P. Green, Pierre Y. Desprez, Primo N. Lara, David R. Gandara, Philip C. Mack, Hsing-Jien Kung
Journal: Cancer Research
Cancer Res (2008) 68 (7): 2250–2258.
https://doi.org/10.1158/0008-5472.CAN-07-6403
Published: 01 April 2008
View article titled, Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer
Open the PDF for Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer in another window
Includes: Supplementary data